Table 3.

Good adherence^* to guideline recommended medications according to study setting and period of follow-up

Time point/countries	ACEI/ARB	Antiplatelet	Beta blocker	Statin
3 months†
US	74%26	76%−77%30,35	77%26	78%26
Canada & European countries‡	-	-	-	-
6 months§
US	68%23	-	70%23	70%23
Canada & European countries‡	-	-	-	-
9 months§
US	-	-	-	-
Canada & European countries‡	59%22	75%22	58%22	68%22
1 year§
US	54%−62%23,32	67%−69%21,29	64%−65%23,32	57%−65%23,32
Canada & European countries‡	69%−74%25,28,37	71%−86%28,37	57%−74%25,28,34,36,37	66%−81%25,28,34,37
30 months§
US	-	-	-	-
Canada & European countries‡	77%31	82%31	68%31	64%−77%24,31

^*Proportion of patients who achieved “good adherence”, according to a predetermined study-specific cut-off (Table 2), to medication

^†Estimated using self-reported measure²⁶ or Electronic Medication Monitors^30,35

^‡All these countries have universal health coverage

^§Estimated using Medication Possession Ratio (MPR)^{21,23,29,31,33} or Proportion of days covered (PDC)^{22,24,25,27,28,32,34,36,37}